Written by The South America Genetic Testing Market is expanding as advances in genomic technology and growing awareness of genetic health create greater demand for testing services. The market was valued at USD 1.064 billion in 2024 and is projected to reach USD 1.753 billion by 2035, growing at a CAGR of 4.64% during 2025–2035. Increasing healthcare investment and interest in personalized medicine are supporting this development.
Genetic testing is becoming increasingly relevant in reproductive health, cancer screening, hereditary disease diagnosis, and predictive healthcare. Prenatal testing currently represents a major application area, while newborn screening is gaining momentum as healthcare systems place greater emphasis on early detection. Carrier and diagnostic testing are also creating opportunities across the region.
Technological improvements are helping make genetic testing more accurate and accessible. Panel tests currently account for a significant share of testing activity, while whole exome sequencing is emerging as a rapidly developing area. Next-generation sequencing and advanced genomic analysis are helping healthcare professionals obtain more detailed information for diagnosis and treatment planning.
Brazil remains the largest market in South America, while Mexico is identified as a rapidly developing market. Continued investment in healthcare infrastructure, regulatory development, biotechnology, and personalized medicine is expected to support future growth. Major companies such as Illumina, Thermo Fisher Scientific, Roche, Myriad Genetics, 23andMe, Invitae, and Fulgent Genetics are contributing to the competitive landscape.
Strengthen your strategy with data-backed research insights:
Smart Medical Devices Market Size
Smart Medical Devices Market Share
Smart Medical Devices Market Trends